Paul Eckburg, MD

Acting Chief Medical Officer

Paul Eckburg, MD, currently serves as acting chief medical officer at Zavante Therapeutics, and has worked in clinical research and anti-infective drug development for 17 years. Dr. Eckburg currently serves as an infectious diseases consultant in antibiotic development and was previously employed at Cerexa, a wholly-owned subsidiary of Forest Laboratories, where he was the senior director of the ceftaroline fosamil (Teflaro®) program through FDA approval. In 2000, he formed Eckburg Medical Consulting to provide Phase 1-4 expertise to pharmaceutical companies, and he was involved in the development of multiple approved anti-infective products such as anidulafungin (Eraxis®), doripenem (Doribax®), inhaled levofloxacin (Quinsair™) and ceftazidime-avibactam (Avycaz®). Dr. Eckburg received his bachelor’s degree in cell and structural biology from the University of Illinois at Urbana-Champaign and his medical doctorate from Rush University. He completed his internal medicine residency and infectious diseases fellowship at Stanford University School of Medicine, where he continues to serve as an adjunct clinical assistant professor.